MGMT and type 2 diabetes mellitus: MiR-222-3p targets at least three experimentally validated genes of which low levels have been associated with T2D pathology: O-6-Methylguanine-DNA Methyltransferase (MGMT), Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B-α isoform (PPP2R2A), and Reversion Inducing Cysteine Rich Protein With Kazal Motifs (RECK) (62, 63).